Werewolf Reports No Revenue in Fiscal Q2
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 14 2025
0mins
Should l Buy HOWL?
Source: NASDAQ.COM
Financial Performance: Werewolf Therapeutics reported a GAAP EPS loss of $0.468 in Q2 2025, with no revenue generated, reflecting a decline from the previous year but aligning with expectations. Research and development expenses decreased by 14.4%, and the company maintains a cash runway into Q4 2026.
Clinical Development Focus: The company is advancing its lead assets, WTX-124 and WTX-330, through clinical trials while also innovating new products like WTX-1011 for prostate cancer. Key upcoming events include interim clinical data releases and regulatory discussions with the FDA planned for late 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HOWL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HOWL
Wall Street analysts forecast HOWL stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 0.781
Low
1.00
Averages
4.00
High
7.00
Current: 0.781
Low
1.00
Averages
4.00
High
7.00
About HOWL
Werewolf Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. It is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. It is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Werewolf Therapeutics Q4 Earnings Beat Expectations
- Earnings Surprise: Werewolf Therapeutics reported a Q4 GAAP EPS of -$0.20, beating expectations by $0.14, indicating an improvement in financial performance despite still being in a loss position.
- Cash Flow Status: As of December 31, 2025, the company's cash and cash equivalents stood at $57.1 million, down from $65.7 million as of September 30, 2025, reflecting challenges in operational cash management.
- Sufficient Funding: The company believes that its cash reserves as of December 31, 2025, will be adequate to cover operational expenses and capital requirements into Q4 2026, providing assurance for ongoing operations.
- Future Outlook: Despite current financial pressures, the company's optimism regarding future cash sufficiency suggests a degree of flexibility and resilience in its strategic planning.
See More
WEREWOLF THERAPEUTICS REPORTS Q4 NET LOSS OF USD 8.381 MILLION
Company Overview: Werewolf Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and other diseases.
Financial Performance: The company reported a net income of USD 8.381 million for the fourth quarter.
See More
Werewolf Therapeutics Cuts Workforce by 64% to Reduce Costs
- Workforce Reduction: Werewolf Therapeutics announced a 64% workforce cut to lower operating costs, with the reduction expected to be “substantially completed” by February 13, indicating an urgent response to financial pressures.
- One-Time Charge: The company anticipates incurring a one-time charge of $4.1 million in Q1, covering employee separation benefits including severance, which will negatively impact its short-term financial outlook.
- Executive Departures: CFO Timothy W. Trost and CMO Randi Isaacs will resign, receiving severance equal to nine months of their base salary, highlighting the risks associated with executive turnover during the restructuring process.
- Strategic Evaluation: The company is evaluating strategic partnerships for further development of its WTX-124 and WTX-330 INDUKINE programs, although there is no guarantee of successful financing or transactions, reflecting challenges in securing operational funding.
See More
Werewolf Therapeutics Board Approves Key Decision
- Board Decision: Werewolf Therapeutics announced on Friday in a regulatory filing that its board has approved a significant decision, although specific details remain undisclosed, this move could impact the company's future strategic direction.
- Regulatory Filing Submission: The announcement was made through a regulatory filing, indicating the company's commitment to transparency and compliance, which may enhance investor confidence.
- Market Reaction Anticipation: While specific details are currently unavailable, the market's reaction to the board's decision could influence Werewolf Therapeutics' stock performance, prompting investors to closely monitor subsequent information.
- Strategic Implications: The board's approval may signal a major shift in the company's R&D or business expansion efforts, reflecting its focus on future growth opportunities.
See More
GH Research (GHRS) Stock Surges 22.36% Ahead of Key Update
- Stock Surge: GH Research PLC's stock surged 22.36% to $16.20, gaining $2.96, primarily driven by investor anticipation for a key company update scheduled for January 5, 2026.
- Key Update Announcement: The company will disclose the status of its Investigational New Drug Application (IND) for GH001 and progress on its global pivotal Phase 3 program for treatment-resistant depression (TRD), which is expected to have significant implications for the treatment landscape.
- Investor Interest Spike: The strong investor interest surrounding the upcoming announcement has led to a substantial increase in GH Research's stock price, reflecting heightened market confidence in the biotech sector.
- Positive Market Reaction: Despite no new updates from other biotech firms like Phathom Pharmaceuticals and Forte Biosciences, their stock prices also rose, indicating a broader optimistic sentiment in the biotechnology industry.
See More
Werewolf Reports 30% Response Rate for WTX-124 Monotherapy in Melanoma Patients
- Clinical Data Highlight: WTX-124 demonstrated a 30% overall response rate as a monotherapy in post-ICI advanced melanoma patients, indicating its potential as a best-in-class tolerability drug.
- Efficacy Validation: Initial data from WTX-330 further confirmed its antitumor activity and favorable tolerability, building on the first-in-human trial, showcasing its prospects in challenging tumor types.
- Future Development Plans: The Phase 1/1b trial for WTX-124 is expected to complete in the first half of 2026, with additional data updates planned, potentially requiring further funding to initiate a registration trial.
- Strategic Partnership Opportunities: Werewolf is seeking strategic partners to advance the WTX-124 and WTX-330 INDUKINE programs, leveraging its unique INDUCER T cell engager platform to enhance market competitiveness.
See More
Werewolf Therapeutics Q4 Earnings Beat Expectations
- Earnings Surprise: Werewolf Therapeutics reported a Q4 GAAP EPS of -$0.20, beating expectations by $0.14, indicating an improvement in financial performance despite still being in a loss position.
- Cash Flow Status: As of December 31, 2025, the company's cash and cash equivalents stood at $57.1 million, down from $65.7 million as of September 30, 2025, reflecting challenges in operational cash management.
- Sufficient Funding: The company believes that its cash reserves as of December 31, 2025, will be adequate to cover operational expenses and capital requirements into Q4 2026, providing assurance for ongoing operations.
- Future Outlook: Despite current financial pressures, the company's optimism regarding future cash sufficiency suggests a degree of flexibility and resilience in its strategic planning.
See More
WEREWOLF THERAPEUTICS REPORTS Q4 NET LOSS OF USD 8.381 MILLION
Company Overview: Werewolf Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and other diseases.
Financial Performance: The company reported a net income of USD 8.381 million for the fourth quarter.
See More
Werewolf Therapeutics Cuts Workforce by 64% to Reduce Costs
- Workforce Reduction: Werewolf Therapeutics announced a 64% workforce cut to lower operating costs, with the reduction expected to be “substantially completed” by February 13, indicating an urgent response to financial pressures.
- One-Time Charge: The company anticipates incurring a one-time charge of $4.1 million in Q1, covering employee separation benefits including severance, which will negatively impact its short-term financial outlook.
- Executive Departures: CFO Timothy W. Trost and CMO Randi Isaacs will resign, receiving severance equal to nine months of their base salary, highlighting the risks associated with executive turnover during the restructuring process.
- Strategic Evaluation: The company is evaluating strategic partnerships for further development of its WTX-124 and WTX-330 INDUKINE programs, although there is no guarantee of successful financing or transactions, reflecting challenges in securing operational funding.
See More
Werewolf Therapeutics Board Approves Key Decision
- Board Decision: Werewolf Therapeutics announced on Friday in a regulatory filing that its board has approved a significant decision, although specific details remain undisclosed, this move could impact the company's future strategic direction.
- Regulatory Filing Submission: The announcement was made through a regulatory filing, indicating the company's commitment to transparency and compliance, which may enhance investor confidence.
- Market Reaction Anticipation: While specific details are currently unavailable, the market's reaction to the board's decision could influence Werewolf Therapeutics' stock performance, prompting investors to closely monitor subsequent information.
- Strategic Implications: The board's approval may signal a major shift in the company's R&D or business expansion efforts, reflecting its focus on future growth opportunities.
See More
GH Research (GHRS) Stock Surges 22.36% Ahead of Key Update
- Stock Surge: GH Research PLC's stock surged 22.36% to $16.20, gaining $2.96, primarily driven by investor anticipation for a key company update scheduled for January 5, 2026.
- Key Update Announcement: The company will disclose the status of its Investigational New Drug Application (IND) for GH001 and progress on its global pivotal Phase 3 program for treatment-resistant depression (TRD), which is expected to have significant implications for the treatment landscape.
- Investor Interest Spike: The strong investor interest surrounding the upcoming announcement has led to a substantial increase in GH Research's stock price, reflecting heightened market confidence in the biotech sector.
- Positive Market Reaction: Despite no new updates from other biotech firms like Phathom Pharmaceuticals and Forte Biosciences, their stock prices also rose, indicating a broader optimistic sentiment in the biotechnology industry.
See More
Werewolf Reports 30% Response Rate for WTX-124 Monotherapy in Melanoma Patients
- Clinical Data Highlight: WTX-124 demonstrated a 30% overall response rate as a monotherapy in post-ICI advanced melanoma patients, indicating its potential as a best-in-class tolerability drug.
- Efficacy Validation: Initial data from WTX-330 further confirmed its antitumor activity and favorable tolerability, building on the first-in-human trial, showcasing its prospects in challenging tumor types.
- Future Development Plans: The Phase 1/1b trial for WTX-124 is expected to complete in the first half of 2026, with additional data updates planned, potentially requiring further funding to initiate a registration trial.
- Strategic Partnership Opportunities: Werewolf is seeking strategic partners to advance the WTX-124 and WTX-330 INDUKINE programs, leveraging its unique INDUCER T cell engager platform to enhance market competitiveness.
See More
